It is possible that the residual ability to produce ROS in XLA patients depend on a greater efficacy of DAG-dependent stimulation of PKC, an enzyme normally maintained in an inactive conformation [58–60]. This evidence concerns the gene PRRT2 and Bruton-type agammaglobulinemia.